PMCF Planning as per EU MDR

Author: Turacoz Group
August 25, 2020

As the Medical Device Regulation (MDR) deadlines are approaching for re-certification and/or introduction of new products, manufacturers are also working to start or fulfil the Post-market Clinical Follow-up (PMCF) activities as per requirements set out in Annex XIV, part B of the MDR.

The Annex states “PMCF shall be understood to be a continuous process that updates the clinical evaluation referred to in Article 61 and Part A of this Annex and shall be addressed in the manufacturer’s post-market surveillance plan”.

The purpose of PMCF is:

a) to gather information regarding:

  • rare complications
  • clinical observations only seen in a larger user/patient population
  • clinical observations only seen after long-term use of the device

b)  verification of clinical risk-benefit analysis conclusions

PMCF requirements as per EU MDR

A successful PMCF plan ensures that safety and performance results are continuously available to the market. PMCF should be carried out to proactively collect and evaluate clinical data per the method laid out in the PMCF plan which aims at:

  • confirming the safety and performance throughout the product lifecycle
  • identifying risks and previously unknown side-effects while continually monitoring already identified side-effects and contraindications,
  • ensuring the continued acceptability of the benefit-risk ratio, and
  • identifying off-label uses of the device, while ensuring the intended purpose is correct in the environment it is supposed to be used.

If through PMCF, the need for preventive and/or corrective measures has been identified, the manufacturer must implement them and update the post market surveillance report accordingly.

Therefore, PMCF plan specifies the methods and procedures that will be used to proactively collect and evaluate clinical data in relation to the product’s safety as well as clinical performance.

PMCF Planning Pitfalls

Some of the most common pitfalls in planning a prospective clinical PMCF plan are: 

a) Time-consuming ethical approval

Overall delay in planning a PMCF study might happen due to requirement of approval from ethical committees, which can be a time-consuming task as requirements may vary from country to country.

b) GDPR Compliance

The GDPR is a comprehensive regulation which can help identify the safety, performance, and risk profile specific to your device. The key to compliance lies in selecting systems that guarantee the correct security and safety measures and obtaining clear informed consent from respondents/patients. 

c) Key Opinion Leaders

It is important to collaborate with a network of key opinion leaders in the region you are seeking approval as conducting as planning a PMCF study requires correct and relevant data reported to ensure the safety and performance profile of the device is rightly captured. Clinical experts in the region can help assess and guide these requirements as they have expertise in the filed due to their exposure to working with such devices.

 

You Might Also Like

  • Top Benefits of Using Academic Research Writing Services

    “Write the paper as though no editor will ever see it … then let a good editor make sure everyone

  • World Thyroid Day 2025: How AI Is Revolutionizing Thyroid Health

    World Thyroid Day invites us to appreciate the tiny, butterfly-shaped gland with a big job in managing our body’s energy,

  • How AI is redefining content creation in pharma — And why humans are still the drivers of trust

    In an era where speed, efficiency, and personalization have become imperatives, Artificial Intelligence (AI) — particularly machine learning, AI algorithms,

  • World Thalassemia Day 2025: Giving a Voice to the Global Patient Community

    Every 8 May, World Thalassemia Day shines an international spotlight on the millions of people living with this inherited genetic disorder.

  • Decoding Ovarian Cancer Symptoms: Communicating the Silent Signs

    Ovarian cancer remains one of the most challenging gynaecologic malignancies, often referred to as a “silent killer” due to its subtle onset and late-stage diagnosis.1 In 2022, 324,603 women worldwide were diagnosed with ovarian cancer.

  • 4 Ways in Which HEOR is Transforming Healthcare with RWE

    The healthcare landscape is being reshaped at an unprecedented pace, powered by sophisticated data analytics, emerging technologies, and the escalating

  • The Role of HEOR in Payer Decisions to Switch from Originators to Biosimilars

    Biosimilars—biologic medicines that are highly similar to FDA-approved originator biologics—offer a cost-effective alternative without compromising clinical efficacy.1,2 Since the first

  • Content’s Industrial Revolution: Shaping the Future of Pharma

    Communications In a rapidly evolving digital ecosystem, the pharmaceutical industry’s relationship with content is undergoing a seismic shift. At the

  • Health Journalism: Combating Misinformation with Accuracy

    By Turacoz Healthcare Solutions | World Liver Day 2025 In a world where social media dominates wellness discussions, liver health

  • Patient Voices Matter: How Patient-reported Outcomes Are Redefining Market Access

    The healthcare industry is experiencing a paradigm shift as patient voices take center stage in drug development and approval processes.

Newsletter

Stay informed with the latest trends, insights, and updates in medical communications—download our newsletter now.

partner with us

Partner with Turacoz to bring science to life through strategic and evidence-based communication.

Partner with Us